A Phase 3 interventional study of SM-13496 40mg and SM-13496 80mg in Schizophrenia, sponsored by Sumitomo Pharma Co., Ltd.. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-12.
Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 8th largest by enrollment, is one of 5 that started in 2012, is one of 18 in phase 3, and was the 22nd registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2012.
This study's enrollment of 457 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
Sumitomo Pharma Co., Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 9th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2012, is one of 21 in phase 3, and was the 23rd registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SM-13496 40mg
Drug: SM-13496 80mg
Drug: Placebo
once daily orally
once daily orally
once daily orally
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.
Time frame: Baseline and 6 week
Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6
CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease. The change from baseline in CGI-S score (repeated measures) at each visit during the treatment phase is presented for the mITT population
Time frame: Baseline and 6 weeks
Change From Baseline in PANSS Positive Subscale Scores at Week 6
The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Time frame: Baseline and 6 weeks
Change From Baseline in PANSS Negative Subscale Scores at Week 6
The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Time frame: Baseline and 6 weeks
Change From Baseline in PANSS General Psychopathology Subscale Scores at Week 6
The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.
Time frame: Baseline and 6 weeks
Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)
Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.
Time frame: From Baseline to 6 weeks
Proportion of Participants With TEAEs Leading to Discontinuation
Time frame: From Baseline to 6 weeks
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)
Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.
Time frame: From Baseline to 6 weeks
| Milestone | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| Started | 150 | 155 | 152 |
| Completed | 106 | 116 | 110 |
| Not completed | 44 | 39 | 42 |
The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.
| units on a scale | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 | -17.9 ± 1.72 | -17.3 ± 1.67 | -13.1 ± 1.72 |
CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease. The change from baseline in CGI-S score (repeated measures) at each visit during the treatment phase is presented for the mITT population
| units on a scale | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6 | -0.86 ± 0.100 | -0.97 ± 0.097 | -0.79 ± 0.101 |
The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
| units on a scale | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| Change From Baseline in PANSS Positive Subscale Scores at Week 6 | -5.4 ± 0.54 | -6.2 ± 0.52 | -4.2 ± 0.54 |
The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
| units on a scale | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| Change From Baseline in PANSS Negative Subscale Scores at Week 6 | -3.9 ± 0.46 | -3.4 ± 0.45 | -2.9 ± 0.46 |
The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.
| units on a scale | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| Change From Baseline in PANSS General Psychopathology Subscale Scores at Week 6 | -8.8 ± 0.85 | -7.9 ± 0.83 | -6.3 ± 0.85 |
Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.
| Participants | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| Proportion of Participants With Treatment-emergent Adverse Events (TEAEs) | 103 | 107 | 97 |
| Participants | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| Proportion of Participants With TEAEs Leading to Discontinuation | 11 | 11 | 16 |
Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.
| Participants | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs) | 4 | 3 | 3 |
Collected over From Baseline to 6 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SM-13496 (Lurasidone HCl) 40mg | — | 4/150 (2.7%) | 99/150 (66%) |
| SM-13496 (Lurasidone HCl) 80mg | — | 3/154 (1.9%) | 104/154 (67.5%) |
| Placebo | — | 3/151 (2%) | 94/151 (62.3%) |
| Event | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 3/150 | 3/154 | 1/151 |
| Psychotic disorderPsychiatric disorders | 1/150 | 0/154 | 0/151 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/150 | 0/154 | 1/151 |
| AnxietyPsychiatric disorders | 0/150 | 0/154 | 1/151 |
| Event | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo |
|---|---|---|---|
| AkathisiaNervous system disorders | 11/150 | 16/154 | 5/151 |
| HeadacheNervous system disorders | 14/150 | 6/154 | 12/151 |
| ConstipationGastrointestinal disorders | 13/150 | 5/154 | 12/151 |
| SchizophreniaPsychiatric disorders | 6/150 | 6/154 | 12/151 |
| NauseaGastrointestinal disorders | 11/150 | 12/154 | 7/151 |
| AnxietyPsychiatric disorders | 11/150 | 11/154 | 8/151 |
| NasopharyngitisInfections and infestations | 9/150 | 11/154 | 7/151 |
| InsomniaPsychiatric disorders | 10/150 | 11/154 | 6/151 |
| VomitingGastrointestinal disorders | 9/150 | 9/154 | 3/151 |
| SomnolenceNervous system disorders | 9/150 | 4/154 | 1/151 |
| Age, Continuous(years) | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 42.0 ± 13.1 | 43.6 ± 13.9 | 42.9 ± 13.5 | 42.9 ± 13.5 |
| Sex: Female, Male(Participants) | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo | Total |
|---|---|---|---|---|
| Female | 65 | 73 | 58 | 196 |
| Male | 80 | 79 | 84 | 243 |
| Region of Enrollment(participants) | SM-13496 (Lurasidone HCl) 40mg | SM-13496 (Lurasidone HCl) 80mg | Placebo | Total |
|---|---|---|---|---|
| Japan | 62 | 66 | 60 | 188 |
| Taiwan | 19 | 21 | 19 | 59 |
| Korea, Republic of | 43 | 42 | 43 | 128 |
| Malaysia | 21 | 23 | 20 | 64 |
The record gives a start of Jul 2012, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone